Company intelligence / Profile preview

InfectoTest

Ownership: Private
Development stage: Preclinical

Overview

InfectoTest has developed "InfectoSynovia," a rapid (<5 min), high-sensitivity and specificity point-of-care test for diagnosing periprosthetic joint infections using minimal synovial fluid. The technology uses electrochemical analysis and software-aided interpretation. No clinical trial results or regulatory approvals are reported yet; the product remains in development. Biocomposites has made a minority investment to accelerate commercialization. The company aims to address the growing need for fast PJI diagnosis as joint replacements increase globally.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test (Point-of-care diagnostic system)
Industry: Metabolite Diagnostics

Drug pipeline

1 asset

InfectoSynovia

Pre-clinical

Indications: Periprosthetic joint infection

Partnerships

Biocomposites (minority investor and strategic partner)

Beyond the preview

Go deeper on InfectoTest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InfectoTest.

Explore the full profile